Besides, EPHA4 may be applied in the molecular diagnosis of Sézary syndrome-related cutaneous T-cell lymphomas, and the membrane-bound EPHA4 receptor can serve as a target for targeted therapeutic interventions [28]. Here, EPHA4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.